共 50 条
The Effect of Biologic Agents on Steatotic Liver Disease in Patients with Inflammatory Bowel Disease: A Prospective, Open-Label Comparative Trial
被引:0
作者:
Papaefthymiou, Apostolis
[1
,2
]
Sarrou, Styliani
[3
]
Pateras, Konstantinos
[4
]
Vachliotis, Ilias D.
[1
,4
]
Agrotis, Georgios
[5
]
Sgantzou, Ioanna-Konstantina
[5
]
Perifanos, Georgios
[6
]
Kapsoritakis, Andreas
[2
]
Speletas, Matthaios
[3
]
Vlychou, Marianna
[5
]
Dalekos, George N.
[6
]
Potamianos, Spyros
[2
]
Goulas, Antonis
[1
]
Kountouras, Jannis
[7
]
Polyzos, Stergios A.
[1
]
机构:
[1] Aristotle Univ Thessaloniki, Sch Med, Lab Pharmacol 1, Thessaloniki 54124, Greece
[2] Univ Thessaly, Univ Hosp Larissa, Sch Med, Dept Gastroenterol, Larisa 41100, Greece
[3] Univ Thessaly, Fac Med, Dept Immunol & Histocompatibil, Larisa 41100, Greece
[4] 424 Gen Mil Training Hosp, Dept Gastroenterol, Thessaloniki 56429, Greece
[5] Univ Gen Hosp Larissa, Dept Radiol, Larisa 41100, Greece
[6] Gen Univ Hosp Larissa, Natl Expertise Ctr Greece Autoimmune Liver Dis, Dept Med, Res Lab Internal Med, Larisa 41110, Greece
[7] Aristotle Univ Thessaloniki, Ippokrat Hosp, Sch Med, Med Clin 2, Thessaloniki 54642, Greece
关键词:
biologics;
inflammatory bowel diseases;
metabolic-dysfunction associated steatotic liver disease;
metabolic-dysfunction associated steatohepatitis;
nonalcoholic fatty liver disease;
nonalcoholic steatohepatitis;
METABOLIC SYNDROME;
CROHNS-DISEASE;
INSULIN-RESISTANCE;
MANIFESTATIONS;
FIBROSIS;
SCORE;
D O I:
10.3390/ph17111432
中图分类号:
R914 [药物化学];
学科分类号:
100701 ;
摘要:
Background: Biologic agents used in patients with inflammatory bowel diseases (IBD) may influence the pathophysiology of coexistent metabolic-dysfunction associated steatotic liver disease (MASLD). This study primarily aimed to evaluate the six-month effect of infliximab or vedolizumab vs. no biologics on presumed hepatic steatosis in patients with IBD. Secondary endpoints were their effect on hepatic fibrosis and parameters related to hepatic metabolism. Methods: This prospective, non-randomized, controlled trial assigned adult bio-na & iuml;ve patients with IBD into three groups: infliximab, vedolizumab, or controls (receiving no biologic). The baseline was the time of the initiation of biologic agents and the endpoint six months later. Hepatic steatosis was evaluated with transabdominal ultrasonography (Hamaguchi score), whereas controlled attenuation parameter (CAP), fatty liver index (FLI), and hepatic steatosis index (HSI) were used as surrogates. Hepatic fibrosis was evaluated with liver stiffness (LS), fibrosis-4 index (FIB-4), and nonalcoholic fatty liver disease (NAFLD) fibrosis score. Results: Sixty-six patients were assigned to infliximab (n = 26), vedolizumab (n = 14), or control (n = 26); At the endpoint, the Hamaguchi score, CAP, FLI, and HSI were not different between groups. LS was not different between groups; however, FIB-4 was increased within all groups, and NAFLD fibrosis score was increased within infliximab and control groups, without significant biologic x time interactions. Conclusions: No positive or adverse effect of infliximab or vedolizumab vs. no biologic agents was shown on presumed hepatic steatosis in patients with IBD, who have not been previously exposed to biologic agents. Although no effect of both biologic agent on LS, a slight but significant increase in FIB-4 and NAFLD fibrosis score warrants further studying.
引用
收藏
页数:16
相关论文
共 50 条